BioPharmSignal logoBioPharmSignal

Biotech News

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Inhibikase Therapeutics (IKT)Inhibikase TherapeuticsClinical readout

IKT (IKT) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ikt.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

ELVNEnliven Therapeutics2026-06-03 20:05 EST

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

KYMRKymera2026-06-25 11:00 EST

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

IKTInhibikase Therapeutics2026-07-14 12:00 EST

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

IDYAIDEAYA Biosciences2026-06-01 15:00 EST

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO

COGTCogent Biosciences2026-05-30 12:00 EST

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

IDYAIDEAYA Biosciences2026-07-27 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

View all latest news

Inhibikase Therapeutics

Pulmonary Hypertension Company Inhibikase Therapeutics develops IKT-001 for pulmonary arterial hypertension. IKT-001 The candidate is a differentiated formulation of imatinib intended to retain pulmonary vascular activity while improving tolerability and long-term usability. IMPROVE-PAH The registrational Phase 3 IMPROVE-PAH study is...

Recent company news

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

IKTInhibikase Therapeutics2026-07-14 12:00 EST

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

IKTInhibikase Therapeutics2026-07-02 20:01 EST

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IKTInhibikase Therapeutics2026-05-12 20:01 EST

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

IKTInhibikase Therapeutics2026-04-07 12:00 EST

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Stock data

Close
2.41 USD
Market cap
224.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States